DexCom Dirección

Dirección controles de criterios 4/4

El CEO de DexCom's es Kevin Sayer , nombrado en Jun 2011, tiene una permanencia de 12.83 años. compensación anual total es $15.44M, compuesta por 6.2% salario y 93.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.044% de las acciones de la empresa, por valor de $24.05M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 9.4 años, respectivamente.

Información clave

Kevin Sayer

Chief Executive Officer (CEO)

US$15.7m

Compensación total

Porcentaje del salario del CEO	7.0%
Permanencia del CEO	12.9yrs
Participación del CEO	0.04%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	9.5yrs

Actualizaciones recientes de la dirección

Recent updates

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Oct 21

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

Oct 04

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Sep 24

DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend

Sep 21

DexCom promotes technology chief Leach to COO

Aug 31

DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

Aug 01

DexCom stock down ~7% after hours as Q2 results miss expectations

Jul 28

Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

Jul 13

DexCom: I Wouldn't Buy The Dip

Jul 07

Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Jun 24

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Jun 03

DexCom: Q1'22 Earnings Strong Enough To Maintain Valuation But Not To Increase It

May 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kevin Sayer en comparación con los beneficios de DexCom?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$639m
Dec 31 2023	US$16m	US$1m	US$542m
Sep 30 2023	n/a	n/a	US$377m
Jun 30 2023	n/a	n/a	US$358m
Mar 31 2023	n/a	n/a	US$293m
Dec 31 2022	US$15m	US$953k	US$341m
Sep 30 2022	n/a	n/a	US$244m
Jun 30 2022	n/a	n/a	US$230m
Mar 31 2022	n/a	n/a	US$258m
Dec 31 2021	US$12m	US$900k	US$217m
Sep 30 2021	n/a	n/a	US$577m
Jun 30 2021	n/a	n/a	US$562m
Mar 31 2021	n/a	n/a	US$530m
Dec 31 2020	US$14m	US$800k	US$550m
Sep 30 2020	n/a	n/a	US$231m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$10m	US$691k	US$101m
Sep 30 2019	n/a	n/a	-US$171m
Jun 30 2019	n/a	n/a	-US$170m
Mar 31 2019	n/a	n/a	-US$130m
Dec 31 2018	US$10m	US$601k	-US$127m
Sep 30 2018	n/a	n/a	US$43m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$8m	US$546k	-US$50m

Compensación vs. Mercado: La compensación total ($USD15.44M) de Kevin está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Kevin ha sido consistente con los resultados de la empresa en el último año.

CEO

Kevin Sayer (65 yo)

12.9yrs

Permanencia

US$15,712,244

Compensación

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Sayer	Executive Chairman	12.9yrs	US$15.71m	0.044% $ 21.9m
Jereme Sylvain	Executive VP	4.2yrs	US$4.25m	0.0081% $ 4.0m
Jacob Leach	Executive VP & COO	1.8yrs	US$4.94m	0.065% $ 32.4m
Michael Brown	Executive VP & Chief Legal Officer	2.3yrs	US$4.34m	0.0021% $ 1.1m
Teri Lawver	Executive VP & Chief Commercial Officer	1.3yrs	US$6.53m	0.0016% $ 826.0k
Girish Naganathan	Executive VP & CTO	1.6yrs	US$4.05m	0.0014% $ 675.8k
Shelly Selvaraj	Senior VP & Chief Information Officer	2.7yrs	sin datos	0.0065% $ 3.2m
Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	no data	sin datos	sin datos
Matthew Dolan	Executive Vice President of Strategy	3.2yrs	sin datos	0.00058% $ 290.4k
Leverne Marsh	Executive Vice President of Marketing	less than a year	sin datos	sin datos
Sadie Stern	Executive VP & Chief Human Resources Officer	3.7yrs	sin datos	0.0056% $ 2.8m
Steven Pacelli	Executive VP & MD of Dexcom Ventures	3.1yrs	US$3.02m	0.022% $ 10.8m

2.7yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DXCM se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Sayer	Executive Chairman	16.5yrs	US$15.71m	0.044% $ 21.9m
Mark Foletta	Lead Independent Director	9.5yrs	US$393.51k	0.015% $ 7.4m
Steven Altman	Independent Director	10.5yrs	US$343.40k	0.013% $ 6.7m
Eric Topol	Independent Director	14.8yrs	US$346.49k	0.094% $ 47.2m
Nicholas Augustinos	Independent Director	14.5yrs	US$362.21k	0.0086% $ 4.3m
Bridgette Heller	Independent Director	4.7yrs	US$346.49k	0.0052% $ 2.6m
Barbara Kahn	Independent Director	13.1yrs	US$348.40k	0.0057% $ 2.8m
Kyle Malady	Independent Director	3.6yrs	US$343.40k	0.0032% $ 1.6m
Karen Dahut	Independent Director	3.8yrs	US$345.90k	0.0031% $ 1.5m
Richard Collins	Independent Director	7.2yrs	US$345.90k	0.0092% $ 4.6m
Rimma Driscoll	Independent Director	less than a year	US$404.72k	0% $ 0

9.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de DXCM se considera experimentada (9.4 años de antigüedad promedio).

DexCom Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive Chairman recently sold US$4.6m worth of stock

Recent updates

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc., Annual General Meeting, May 22, 2024

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Now 24% overvalued after recent price rise

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Executive VP notifies of intention to sell stock

DexCom: A Wealth Compounder In Healthcare

Full year 2023 earnings: EPS exceeds analyst expectations

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold US$4.6m worth of stock

DexCom: Stelo Stellar Outlook

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Insufficient new directors

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Executive Chairman recently sold US$4.8m worth of stock

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Price target increased to US$121

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?